[ad_1]
Nano-Capped Therapix Biosciences Therapy (NASDAQ: TRPX) is up from 13% pre-sale on lumen volume in the wake of its announcement of encouraging preclinical results for THX-160 pain, a CB2 receptor agonist.
The results showed that THX-160 was well tolerated without significant adverse effects. The effectiveness of the badgesic was comparable to that of high dose morphine.
DSI Adi Zuloff-Shani states, "These encouraging data, as well as the published preclinical results on the effectiveness of the CB2R agonist in the relief of pain, reinforce our belief. The drug candidate THX-160 has a favorable safety and efficacy profile that could eventually address the unmet need for well-tolerated and safe oral pain treatments that improve patients' quality of life. continue and develop our cannabinoid platform, and potentially translate into new innovative treatments. "
[ad_2]
Source link
